Literature DB >> 29679038

Ninety-minute daratumumab infusion is safe in multiple myeloma.

Hallie Barr1, Jessica Dempsey2, Allyson Waller2, Ying Huang3, Nita Williams4, Nidhi Sharma4, Don M Benson3, Ashley E Rosko3, Yvonne A Efebera3, Craig C Hofmeister3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29679038      PMCID： PMC6167208          DOI： 10.1038/s41375-018-0120-2

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Drug allergy: an updated practice parameter.

Authors: 
Journal:  Ann Allergy Asthma Immunol       Date:  2010-10       Impact factor: 6.347

Review 2.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.

Authors:  Janos Szebeni
Journal:  Toxicology       Date:  2005-09-02       Impact factor: 4.221

3.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Authors:  María-Victoria Mateos; Meletios A Dimopoulos; Michele Cavo; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Polina Kaplan; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna M Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Christopher Chiu; Jianping Wang; Robin Carson; Wendy Crist; William Deraedt; Huong Nguyen; Ming Qi; Jesus San-Miguel
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

4.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Authors:  Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees
Journal:  Lancet       Date:  2016-01-07       Impact factor: 79.321

5.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

6.  Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.

Authors:  Emily Dotson; Brooke Crawford; Gary Phillips; Jeffrey Jones
Journal:  Support Care Cancer       Date:  2015-08-14       Impact factor: 3.603

7.  Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Authors:  Saad Z Usmani; Brendan M Weiss; Torben Plesner; Nizar J Bahlis; Andrew Belch; Sagar Lonial; Henk M Lokhorst; Peter M Voorhees; Paul G Richardson; Ajai Chari; A Kate Sasser; Amy Axel; Huaibao Feng; Clarissa M Uhlar; Jianping Wang; Imran Khan; Tahamtan Ahmadi; Hareth Nahi
Journal:  Blood       Date:  2016-05-23       Impact factor: 22.113

8.  The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells.

Authors:  Rut Olivar; Ana Luque; Sonia Cárdenas-Brito; Mar Naranjo-Gómez; Anna M Blom; Francesc E Borràs; Santiago Rodriguez de Córdoba; Peter F Zipfel; Josep M Aran
Journal:  J Immunol       Date:  2016-04-13       Impact factor: 5.422

9.  Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.

Authors:  X S Xu; X Yan; T Puchalski; S Lonial; H M Lokhorst; P M Voorhees; T Plesner; K Liu; I Khan; R Jansson; T Ahmadi; Jj Perez Ruixo; H Zhou; P L Clemens
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

10.  FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Authors:  Vishal Bhatnagar; Nicole J Gormley; Lola Luo; Yuan Li Shen; Rajeshwari Sridhara; Sriram Subramaniam; Guoxiang Shen; Lian Ma; Stacy Shord; Kirsten B Goldberg; Ann T Farrell; Amy E McKee; Richard Pazdur
Journal:  Oncologist       Date:  2017-09-13
View more
  18 in total

Review 1.  Antibody-Based Treatment Approaches in Multiple Myeloma.

Authors:  Hitomi Hosoya; Surbhi Sidana
Journal:  Curr Hematol Malig Rep       Date:  2021-03-17       Impact factor: 3.952

2.  Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Authors:  Pellegrino Musto
Journal:  Oncologist       Date:  2018-04-26

Review 3.  Daratumumab for the Treatment of Multiple Myeloma.

Authors:  Torben Plesner; Jakub Krejcik
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

4.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

Review 5.  The Anti-CD38 Antibody Therapy in Multiple Myeloma.

Authors:  Maria Teresa Petrucci; Federico Vozella
Journal:  Cells       Date:  2019-12-12       Impact factor: 6.600

Review 6.  The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.

Authors:  Francesca Bonello; Mariella Grasso; Mattia D'Agostino; Ivana Celeghini; Alessia Castellino; Mario Boccadoro; Sara Bringhen
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-29

7.  Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

Authors:  Mary Slavcev; Allison Spinelli; Elisabeth Absalon; Tara Masterson; Christoph Heuck; Annette Lam; Erwin De Cock
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-08

Review 8.  Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Authors:  Francesca Bonello; Roberto Mina; Mario Boccadoro; Francesca Gay
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

Review 9.  Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).

Authors:  Evangelos Terpos; Monika Engelhardt; Gordon Cook; Francesca Gay; Maria-Victoria Mateos; Ioannis Ntanasis-Stathopoulos; Niels W C J van de Donk; Hervé Avet-Loiseau; Roman Hajek; Annette Juul Vangsted; Heinz Ludwig; Sonja Zweegman; Philippe Moreau; Hermann Einsele; Mario Boccadoro; Jesus San Miguel; Meletios A Dimopoulos; Pieter Sonneveld
Journal:  Leukemia       Date:  2020-05-22       Impact factor: 12.883

Review 10.  Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.

Authors:  Efstathios Kastritis; Ashutosh Wechalekar; Stefan Schönland; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Monique Minnema; Murielle Roussel; Arnaud Jaccard; Ute Hegenbart; Shaji Kumar; Maria T Cibeira; Joan Blade; Meletios A Dimopoulos
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.